(Total Views: 580)
Posted On: 11/28/2022 4:53:22 PM
Post# of 154788
I think the call will be what they say it will be: letting us know about the status of the three indications, each of which will be presented by our expert.
I think the most likely news would be something to do with those indications. Perhaps a Phase III trial protocol has been proposed to the FDA for NASH (we know Recknor has been working on one) and/or for cancer. Larger, more substantive trials with a much better chance at hitting a p value.
If we're really lucky, maybe a combo trial entirely sponsored by the maker of the other drug, or by the NIH.
That would be great, but I'm not betting on it. I think all of us tend to immediately guess that something great is afoot that has nothing to do with what management actually says they are discussing. Along that path disappointment lies.
I think the most likely news would be something to do with those indications. Perhaps a Phase III trial protocol has been proposed to the FDA for NASH (we know Recknor has been working on one) and/or for cancer. Larger, more substantive trials with a much better chance at hitting a p value.
If we're really lucky, maybe a combo trial entirely sponsored by the maker of the other drug, or by the NIH.
That would be great, but I'm not betting on it. I think all of us tend to immediately guess that something great is afoot that has nothing to do with what management actually says they are discussing. Along that path disappointment lies.
(10)
(0)
